Patents Examined by James Wilson
-
Patent number: 7498352Abstract: The present invention provides a TGF-? superfamily production/secretion promoter comprising a compound represented by the formula wherein R1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of dysautonomia, bladder dysfunction, hearing impairment, bone disease and the like.Type: GrantFiled: June 25, 2002Date of Patent: March 3, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuo Sugiyama, Masatoshi Hazama, Asae Shintani
-
Patent number: 7485648Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.Type: GrantFiled: June 14, 2005Date of Patent: February 3, 2009Assignee: Schering CorporationInventors: Julius J. Matasi, Deen Tulshian, Duane A. Burnett, Wen-Lian Wu, Peter Korakas, Lisa S. Silverman, Thavalakulamgara K. Sasikumar, Li Qiang, Martin S. Domalski
-
Patent number: 7465738Abstract: The present invention relates to compounds useful as promoters of the SMN2 gene. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of Spinal Muscular Atrophy.Type: GrantFiled: June 16, 2004Date of Patent: December 16, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jill Jarecki, Xiaocun Chen, Dennis James Hurley, Lewis R. Makings, Mark T. Miller, Brian Pollok, Jeffrey H. Stack, Michael A. Whitney
-
Patent number: 7465741Abstract: The invention concerns substituted tricyclic isoxazoline derivatives according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with at least one radical that is attached to the phenyl radical by a carbon-carbon bond as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherin all variables are defined in claim 1.Type: GrantFiled: August 12, 2003Date of Patent: December 16, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: José Ignacio Andrés-Gil, José Manuel Bartolomé-Nebreda, Rosa Maria Alvarez-Escobar, Margaretha Henrica Maria Bakker, Antonius Adrianus Hendrikus Petrus Megens
-
Patent number: 7462624Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.Type: GrantFiled: June 22, 2007Date of Patent: December 9, 2008Assignee: Incyte CorporationInventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
-
Patent number: 7459458Abstract: Polymorph Form III of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide, and use thereof as a sedative-hypnotic, anxiolytic, anticonvulsant, and/or skeletal muscle relaxant agent. Related compositions and methods are also disclosed, particularly with regard to treatment of insomnia.Type: GrantFiled: December 15, 2004Date of Patent: December 2, 2008Assignee: Neurocrine Biosciences, Inc.Inventors: Scott E. Zook, Donald Hettinger, Henry R. DuBois, III
-
Patent number: 7456191Abstract: This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.Type: GrantFiled: March 22, 2006Date of Patent: November 25, 2008Assignee: Schering AGInventors: Ulrich Luecking, Gerhard Siemeister, Rolf Jautelat
-
Patent number: 7456567Abstract: An organic electroluminescent device having a pair of electrodes, and at least one organic layer interposed between the pair of electrodes, with the organic layer containing at least one compound represented by formula (1): wherein L11, L13, and L14 each independently represent an o-arylene group, an o-heteroarylene group, or a vinylene group; L12 represents an o-arylene group, an o-heteroarylene group, a vinylene group, or an ethylene group; and L15 represents a trivalent or higher aromatic ring or a trivalent or higher aromatic heterocyclic ring; and a compound represented by formula (2): wherein L21, L22, L23, L24, and L25 each independently represent a group necessary for forming an aromatic ring or a group necessary for forming an aromatic heterocyclic ring; and a method for producing a compound represented by formula (2).Type: GrantFiled: September 12, 2005Date of Patent: November 25, 2008Assignee: Fujifilm CorporationInventor: Jun Ogasawara
-
Patent number: 7452892Abstract: The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.Type: GrantFiled: June 16, 2006Date of Patent: November 18, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Gang Wu, Amarendra B. Mikkilineni, Philip M. Sher, Natesan Murugesan, Zhengxiang Gu
-
Patent number: 7449495Abstract: Described and claimed are compounds of Formula (I) in which R, R?, R?, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.Type: GrantFiled: June 20, 2007Date of Patent: November 11, 2008Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Sabrina Dallavalle, Lucio Merlini, Claudio Pisano, Loredana Vesci, Giuseppe Giannini, Sergio Penco
-
Patent number: 7445789Abstract: New biocompatible polymeric systems carrying triflusal or HTB are described which result from the polymerization of a monomer A of the acrylic or vinylic type and carrying triflusal or HTB, wherein triflusal or HTB are linked to the remainder of the molecule of said monomer through an in vivo hydrolysable covalent bond, and optionally a second polymerisable monomer B. These new polymeric systems are useful as coating for synthetic biomaterials.Type: GrantFiled: November 7, 2005Date of Patent: November 4, 2008Assignee: Palau Pharma, S.A.Inventors: Alberto Gallardo Ruiz, Gema Rodriguez Crespo, Julio San Román del Barrio
-
Patent number: 7439249Abstract: The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases.Type: GrantFiled: December 31, 2003Date of Patent: October 21, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeffrey O. Saunders, Gregory F. Miknis, Alexandre J. Buckmelter, Kevin W. Hunt, James F. Blake, Guy P. A. Vigers, Xicheng Sun
-
Patent number: 7432263Abstract: Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.Type: GrantFiled: July 30, 2002Date of Patent: October 7, 2008Assignee: Pfizer Italia, S.r.l.Inventor: Maurizio Pulici
-
Patent number: 7432404Abstract: Acrolein is removed from a process stream such as a process stream generated in the manufacture of acrylonitrile. The process includes reacting the acrolein with a compound containing a reactable thiol or hydroxyl moiety in the presence of an acid catalyst. The present process provides for a refined process stream that contains no more than 5 ppm by weight unreacted acrolein.Type: GrantFiled: February 23, 2007Date of Patent: October 7, 2008Assignee: Solutia, Inc.Inventors: Gregory J. Ward, Bryan C. Blanchard, Scott G. Moffatt, Valerie S. Monical, Richard D. Murphy, Balshekar Ramchandran
-
Patent number: 7425554Abstract: In one aspect, the present invention provides compounds having formula (1) or (100), a salt thereof or a hydrate of the foregoing, which compounds exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome; rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R10 represents optionally substituted cycloalkyl, etc., R20-23 represent hydrogen, alkyl, alkoxy, etc., R30-32 represent hydrogen, alkyl, oxo, etc., and R40 represents optionally substituted alkyl, etc.Type: GrantFiled: December 27, 2004Date of Patent: September 16, 2008Assignee: Eisai R&D Management Co., Ltd.Inventors: Tetsuya Kawahara, Makoto Kotake, Naoki Yoneda, Shinsuke Hirota, Masayoshi Ohkuro
-
Patent number: 7423040Abstract: The present disclosure provides novel pharmaceutical compounds and methods for making the same, novel pharmaceutical dosage forms and methods for making the same, and methods for using said compounds and dosage forms to treat and prevent diseases and/or disorders.Type: GrantFiled: February 16, 2006Date of Patent: September 9, 2008Inventors: Irene Eijgendaal, Gerrit Klein, Maria J. L. Terhorst-Van Amstel, Klaas Zwier, Nico Bruins, Hendrikus T. Rigter, Erik Gout, Caroline Boon, Michiel H. De Vries
-
Patent number: 7423150Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: GrantFiled: October 15, 2004Date of Patent: September 9, 2008Assignee: Novartis AGInventors: Abran Costales, Teresa Hansen, Barry H. Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Joelle Verhagen
-
Patent number: 7423149Abstract: The present invention provides compounds, which, are novel antagonists for D1 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.Type: GrantFiled: December 21, 2004Date of Patent: September 9, 2008Assignee: Schering CorporationInventors: Duane A. Burnett, Wen-Lian Wu, Martin S. Domalski, Mary Ann Caplen, Richard Spring, Jean E. Lachowicz
-
Patent number: 7417040Abstract: Disclosed are fused tricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. The disclosed compounds are useful as inhibitors of 17?-hydroxysteriod dehydrogenase 3 (17?HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer and pharmaceutical compositions comprising such compounds.Type: GrantFiled: February 25, 2005Date of Patent: August 26, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Wen-Ching Han, Raj N. Misra, Hai-Yun Xiao, Derek J. Norris, John S. Tokarski
-
Patent number: 7413881Abstract: A highly deacetylated chitosan obtained from microbial biomass, a method of obtaining chitosan from microbial biomass, and biomass for making chitosan are disclosed. The method includes providing chitin-containing biomass; reacting the chitin-containing biomass in a caustic solution of greater than 25 percent alkali at a reaction temperature greater than 95° C. for a reaction period of at least 10 hours to convert the chitin in the biomass to chitosan; and separating the chitosan from the caustic solution.Type: GrantFiled: June 15, 2005Date of Patent: August 19, 2008Assignee: Cargill, IncorporatedInventors: Weiyu Fan, John A. Bohlmann, James R. Trinkle, James Donald Steinke, Ki-Oh Hwang, Joseph P. Henning